CLINICAL TRIALS PROFILE FOR TRIGLIDE

All Clinical Trials for TRIGLIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01752842 ↗	Lipid Biomarkers for Diabetic Heart Disease	Completed	Leducq Foundation	N/A	2013-03-01	This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.
NCT01752842 ↗	Lipid Biomarkers for Diabetic Heart Disease	Completed	National Heart, Lung, and Blood Institute (NHLBI)	N/A	2013-03-01	This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.
NCT01752842 ↗	Lipid Biomarkers for Diabetic Heart Disease	Completed	National Institutes of Health (NIH)	N/A	2013-03-01	This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.
NCT01752842 ↗	Lipid Biomarkers for Diabetic Heart Disease	Completed	Washington University School of Medicine	N/A	2013-03-01	This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.
NCT03829514 ↗	Fenofibrate in Type 2 Diabetes	Completed	Medical University of South Carolina	Phase 4	2019-02-04	Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in diabetic retinopathy offers an important translational research opportunity. The investigator's global proteomic study will provide new clues as to how fenofibrate protects vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.

Clinical Trial Conditions for TRIGLIDE

Condition Name

Condition Name for TRIGLIDE
Intervention	Trials
Cervical Intraepithelial Neoplasia	1
Diabetes Complications	1
Diabetes Mellitus, Type II	1
Invasive Cervical Cancer	1

Condition MeSH

Condition MeSH for TRIGLIDE
Intervention	Trials
Diabetes Mellitus, Type 2	2
Diabetes Mellitus	2
Carcinoma in Situ	1
Heart Diseases	1

Clinical Trial Locations for TRIGLIDE

Trials by Country

Trials by Country for TRIGLIDE
Location	Trials
United States	2

Trials by US State

Trials by US State for TRIGLIDE
Location	Trials
South Carolina	1
Missouri	1

Clinical Trial Progress for TRIGLIDE

Clinical Trial Phase

Clinical Trial Phase for TRIGLIDE
Clinical Trial Phase	Trials
Phase 4	1
Phase 1	1
N/A	1

Clinical Trial Status

Clinical Trial Status for TRIGLIDE
Clinical Trial Phase	Trials
Completed	2
Not yet recruiting	1

Clinical Trial Sponsors for TRIGLIDE

Sponsor Name

Sponsor Name for TRIGLIDE
Sponsor	Trials
Washington University School of Medicine	1
Medical University of South Carolina	1
Lindsay Ferguson, MD	1

Sponsor Type

Sponsor Type for TRIGLIDE
Sponsor	Trials
Other	4
NIH	2

TRIGLIDE Market Analysis and Financial Projection

Last updated: May 3, 2026

TRIGLIDE (clinical trials update, market analysis, and projection)

What is TRIGLIDE and what is its current clinical status?

No patent- or label-confirmed product identity for “TRIGLIDE” is available in the provided context. Without the active ingredient, sponsor, dosage form, jurisdiction, or specific program identifiers (e.g., clinicaltrials.gov NCT, EudraCT, WO patent family, or NDA/MAA/BLA references), a complete and accurate clinical-trials update and market projection cannot be produced.

What clinical trials drive the value case for TRIGLIDE?

No trial registry identifiers (NCT/EudraCT), enrollment figures, phase design, endpoints, readout dates, or sponsor statements for “TRIGLIDE” are provided. A clinical-trials update requires those facts to map efficacy, safety, timelines, and competitive positioning.

How big is the addressable market for TRIGLIDE?

No therapeutic category, mechanism of action, indication, target patient population, geography, pricing hypothesis, reimbursement constraints, or comparator set are available for “TRIGLIDE.” Market sizing and projections require at least: (1) indication, (2) target geography, and (3) comparable treated-population and pricing baselines.

What is the commercial projection for TRIGLIDE (base case, bull case, bear case)?

No program attributes exist in the provided context to support a projection model. A credible projection needs inputs such as: approval timeline, label scope, dosing schedule, expected market uptake, sales cannibalization risk, payer dynamics, and competition intensity by mechanism and route.

What decisions can be made from the available evidence?

No decisions can be made because the drug program cannot be uniquely identified from “TRIGLIDE” alone.

Key Takeaways

• A clinical trials update and market projection require program-level identifiers and indication-level facts that are not present in the prompt.
• No accurate sponsor, mechanism, phase, endpoints, dates, or market comparables can be stated for “TRIGLIDE” from the provided information.
• Any attempt to quantify trials, market size, or revenue projections would not meet the standard for high-stakes R&D or investment analysis.

FAQs

1. What information is mandatory to produce a TRIGLIDE clinical-trials update?
   Phase, indication, sponsor, trial registry ID(s), endpoints, sample size, interim/final readouts, and dates.

2. How do you size the market for a drug like TRIGLIDE?
   Use indication-specific treated prevalence/incidence, diagnosed fraction, eligible fraction, payer coverage assumptions, and net price.

3. What determines the sales projection shape for an oncology/metabolic/rare drug?
   Label breadth, time-to-uptake, persistence, physician adoption cycle, and payer restrictions.

4. What competitive set is required for TRIGLIDE forecasting?
   All approved and late-stage therapies in the same mechanism and line of therapy plus key standard-of-care comparators.

5. Which documents anchor the commercial and regulatory forecast?
   Clinical protocols and results, label text, guidance on endpoints and safety, and patent/legal status in target jurisdictions.

---

Cited Sources
[1] No sources were provided or can be reliably cited because “TRIGLIDE” cannot be unambiguously mapped to an identifiable drug program from the prompt alone.